Dentsply Sirona Inc (XRAY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges

GuruFocus.com11-08

Revenue: $951 million, representing a 0.5% increase on a reported basis and 1.3% on an organic basis compared to the prior year quarter. Organic Sales Growth: 1.3%, driven by timing of EDS sales with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481434811?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lSPgHvHhv.Cb0wo_01L3zg--~B/aD02NTt3PTIyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/c0cc1ff4908787c5d90e2f123ca90d0a","is_english":true,"pubTime":"2024-11-08 15:11","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481434811","market":"us","top_or_hot":-1,"title":"Dentsply Sirona Inc (XRAY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $951 million, representing a 0.5% increase on a reported basis and 1.3% on an organic basis compared to the prior year quarter.\nOrganic Sales Growth: 1.3%, driven by timing of EDS sales with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/dentsply-sirona-inc-xray-q3-071158098.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dentsply Sirona Inc (XRAY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDentsply Sirona Inc (XRAY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 15:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/dentsply-sirona-inc-xray-q3-071158098.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $951 million, representing a 0.5% increase on a reported basis and 1.3% on an organic basis compared to the prior year quarter.\nOrganic Sales Growth: 1.3%, driven by timing of EDS sales with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/dentsply-sirona-inc-xray-q3-071158098.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XRAY","symbol_name":"登士柏国际","start_time":0,"source_url":"https://finance.yahoo.com/news/dentsply-sirona-inc-xray-q3-071158098.html","article_id":"2481434811","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lSPgHvHhv.Cb0wo_01L3zg--~B/aD02NTt3PTIyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/c0cc1ff4908787c5d90e2f123ca90d0a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481434811","pubTimestamp":1731049918,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $951 million, representing a 0.5% increase on a reported basis and 1.3% on an organic basis compared to the prior year quarter.Organic Sales Growth: 1.3%, driven by timing of EDS sales with distributors.Adjusted EPS: $0.5, up 3% versus the prior year quarter.Operating Cash Flow: $141 million, up 5% compared to the prior year quarter.Share Repurchases: $100 million completed in Q3, with a year-to-date total of $345 million returned to shareholders.Gross Margin: Declined 40 basis points versus prior year due to unfavorable product mix and lower volume.Segment Performance - Essential Dental Solutions: Organic sales increased 7.5%.Segment Performance - Orthodontic and Implant Solutions: Organic sales declined 3.9%.Regional Performance - US: Organic sales increased 5.1%.Regional Performance - Rest of World: Organic sales grew 0.6%.Full Year 2024 Outlook - Adjusted EBITDA Margin: Approximately 17.5%.Full Year 2024 Outlook - Adjusted EPS: Expected to be in the range of $1.82 to $1.86","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"XRAY":"登士柏国际"},"translate_title":"Dentsply Sirona Inc(XRAY)2024年第三季度收益看涨期权亮点：在挑战中实现增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XRAY":1},"content_text":"Revenue: $951 million, representing a 0.5% increase on a reported basis and 1.3% on an organic basis compared to the prior year quarter.\nOrganic Sales Growth: 1.3%, driven by timing of EDS sales with distributors.\nAdjusted EPS: $0.5, up 3% versus the prior year quarter.\nOperating Cash Flow: $141 million, up 5% compared to the prior year quarter.\nShare Repurchases: $100 million completed in Q3, with a year-to-date total of $345 million returned to shareholders.\nLeverage Ratio: Increased slightly to 2.8 times.\nOrganic Sales Decline (Excluding Timing Impacts): 0.8%.\nGross Margin: Declined 40 basis points versus prior year due to unfavorable product mix and lower volume.\nSegment Performance - Essential Dental Solutions: Organic sales increased 7.5%.\nSegment Performance - Orthodontic and Implant Solutions: Organic sales declined 3.9%.\nSegment Performance - Connected Technology Solutions: Organic sales declined 1.4% versus the prior year quarter.\nRegional Performance - US: Organic sales increased 5.1%.\nRegional Performance - Europe: Organic sales declined 2%.\nRegional Performance - Rest of World: Organic sales grew 0.6%.\nFull Year 2024 Outlook - Organic Sales: Expected to be down 2.5% to 3.5%.\nFull Year 2024 Outlook - Net Sales: Expected to be in the range of $3.79 billion to $3.82 billion.\nFull Year 2024 Outlook - Adjusted EBITDA Margin: Approximately 17.5%.\nFull Year 2024 Outlook - Adjusted EPS: Expected to be in the range of $1.82 to $1.86.\n\n\nWarning! GuruFocus has detected 3 Warning Signs with XRAY.\n\nRelease Date: November 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nDentsply Sirona Inc (NASDAQ:XRAY) reported $951 million in revenue for Q3 2024, with organic sales up 1.3%, driven by timing of EDS sales.\nThe launch of Primescan 2 in September contributed to growth in the CAD/CAM segment, marking a milestone in digital dentistry.\nThe company successfully launched Exmark Pro Plus in the US, exceeding full-year projections by the end of Q3.\nDentsply Sirona Inc (NASDAQ:XRAY) has executed over 70% of its phase two transformation activities, aiming for full run-rate savings by the end of 2025.\nThe company has made significant progress in its ERP rollout, with successful deployments in the UK and the US, enhancing operational efficiency.\n\n Negative Points \n\nDentsply Sirona Inc (NASDAQ:XRAY) announced a voluntary suspension of sales, marketing, and shipments of byte aligners and impression kits due to regulatory reviews, impacting revenue.\nThe company recorded a $500 million non-cash after-tax charge related to goodwill in the orthodontic and implant solution segment due to macroeconomic pressures.\nOrganic sales in the orthodontic and implant solution segment declined by 3.9%, with a notable decline in the US and Europe.\nThe company revised its full-year 2024 outlook, expecting organic sales to be down 2.5% to 3.5%, citing market pressures and challenges with byte.\nDentsply Sirona Inc (NASDAQ:XRAY) is facing ongoing macroeconomic challenges, including high interest rates and reduced patient traffic in key markets like Japan and China.\n\n Q & A Highlights \nQ: Can you provide an update on the suspension of BYTE sales and the associated costs? A: Simon Campion, CEO, explained that the suspension is due to a regulatory review and strategic assessment. The company is evaluating the legislative environment, recent performance, and long-term prospects. Glenn Coleman, CFO, added that BYTE's recent quarter revenue was $40 million, but it was dilutive to earnings due to high operating expenses. The company is taking swift action to reduce costs, including ceasing marketing activities and redeploying assets.\nQ: How is the implant business performing, and what are the expectations for growth? A: Simon Campion noted a decline in the value segment of the implant business due to unique events, including challenges in China and the Middle East. The company has not met its internal expectations and is making leadership changes to improve performance. The focus is on communicating the value of their products and expanding sales efforts, particularly in the U.S.\nQ: How are macroeconomic conditions affecting investment versus cost-saving strategies? A: Simon Campion stated that while cost-cutting is necessary, the company cannot cut its way to growth. Investments are being made in areas that stimulate growth, such as implants and aligners, and in improving customer experience through digital platforms. The focus is on reallocating resources to higher-growth categories and enhancing operational efficiency.\nQ: What is the outlook for the CAD/CAM segment, particularly with the launch of Primescan 2? A: Simon Campion reported that Primescan 2 has been well-received, with strong sales since its launch. The company saw the best quarter for scanner units in three years. However, there is a significant delta between wholesale and retail demand, and the company remains cautious due to macroeconomic uncertainties.\nQ: Can you provide more details on the virtual sales team initiative? A: Simon Campion explained that over 75 virtual sales representatives have been hired, with plans to have 100 by Q1 2025. These reps are starting to engage with customers and are expected to generate revenue in 2025. The initiative aims to get closer to customers and create demand across the portfolio, particularly in the Essential Dental Solutions segment.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481434811"}